Tokai Pharmaceuticals Inc. (TKAI) 11.52 $TKAI Tokai

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tokai Pharmaceuticals Inc. (TKAI) 11.52 $TKAI

Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth
Business Wire - Mon Apr 20, 3:01PM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and migration of human pancreatic ductal adenocarcinoma (PDAC) cells.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Medivation Chief Commercial Officer, to its Board of Directors
Business Wire - Mon Apr 13, 3:01PM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced the appointment of Cheryl Cohen, the former Chief Commercial Officer of Medivation, Inc., to its Board of Directors.
MDVN: 128.88 (+0.29), TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals to Present at Upcoming Conferences
Business Wire - Fri Apr 10, 6:00AM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that it will present at two upcoming conferences:
TKAI: 11.52 (-0.35)

Tokai Pharma and Qiagen expand collaboration on prostate cancer drug companion diagnostic
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 3:42PM CDT

TKAI: 11.52 (-0.35), QGEN: 24.93 (-0.15)

Tokai Pharmaceuticals Announces Expansion to Collaboration with Qiagen on the Development of an AR-V7 Companion Diagnostic
Business Wire - Mon Mar 16, 3:00PM CDT
--Tokai Granted Exclusive Right to Qiagen's Circulating Tumor Cell (CTC) Enrichment Technology for use with a Companion Diagnostic Paired with Galeterone
TKAI: 11.52 (-0.35)

QIAGEN Expands Leadership in Liquid Biopsies with New Circulating Tumor Cell Technology for Development of Companion Diagnostics
PR Newswire - Mon Mar 16, 3:00PM CDT
-- Acquisition of technology from AdnaGen enables use of innovative, non-invasive blood tests to analyze circulating tumor cells (CTCs) for personalized healthcare
TKAI: 11.52 (-0.35), QGEN: 24.93 (-0.15)

Tokai Pharmaceuticals reports 4Q loss
Automated Insights - Thu Mar 12, 7:37AM CDT
CAMBRIDGE, Mass. (AP) _ Tokai Pharmaceuticals Inc. (TKAI) on Thursday reported a loss of $6.2 million in its fourth quarter.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals beats by $0.06
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 7:28AM CDT

TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Thu Mar 12, 7:00AM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter and year ended December 31, 2014.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference
Business Wire - Mon Mar 02, 7:00AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Jodie Morrison, President and Chief Executive Officer, will provide a company overview at the Cowen and Company 35th Annual Health Care Conference in Boston, MA on Wednesday, March 4 at 8am ET.
TKAI: 11.52 (-0.35)

Asco-GU Preview: First-Line Prostate Cancer Chemo Not Dead Yet
EP Vantage - Seeking Alpha - Tue Feb 24, 8:03AM CST
As two leading prostate cancer drugs, Medivation ’s (NASDAQ: MDVN ) Xtandi and Johnson & Johnson ’s (NYSE: JNJ ) Zytiga , battle it out for dominance in the all-important pre-chemotherapy setting, a small study is set to...
MDVN: 128.88 (+0.29), JNJ: 100.43 (+0.13), TKAI: 11.52 (-0.35), SNY: 51.59 (+0.03)

Tokai Pharmaceuticals Provides Companion Diagnostic Update
Business Wire - Mon Jan 12, 8:30AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), today announced that it has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company's lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.
TKAI: 11.52 (-0.35)

Stephen Buckley, Jr. Appointed to Tokai Board of Directors
Business Wire - Fri Jan 09, 7:16AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Stephen Buckley, Jr. has joined the company's board of directors and will serve as chair of the audit committee.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer (CRPC) Including Those Showing a Variant Form of Prostate Cancer Resistant to Hormone Therapy
Business Wire - Wed Nov 19, 7:05AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) today announced updated interim results from its ongoing ARMOR2 Phase 2 clinical trial of galeterone in castration-resistant prostate cancer (CRPC) patients. These interim results from the trial support the potential of galeterone to treat CRPC expressing androgen receptor (AR) splice variants, including AR-V7. The presence of AR C-terminal loss generally, and AR-V7 specifically, has been linked to poor responsiveness to hormonal agents commonly used to treat CRPC.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals, Inc. (Nasdaq: TKAI) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Nov 14, 9:43AM CST
What:
TKAI: 11.52 (-0.35), NDAQ: 48.84 (+0.12)

Tokai Pharmaceuticals EPS of -$2.71
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:37AM CST

TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 7:02AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter ended September 30, 2014.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Announces Interim Phase 2 Data on Galeterone in Patients with Advanced Prostate Cancer to be Presented at the EORTC-NCI-AACR Symposium
Business Wire - Wed Nov 05, 7:01AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that updated, interim results from the company's ongoing Phase 2 clinical trial, ARMOR2, of its lead drug candidate, galeterone, in patients with castration resistant prostate cancer (CRPC) will be presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held November 18-21 in Barcelona, Spain. The presentation entitled, "Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2" will be presented by Mary-Ellen Taplin, M.D., Associate Professor of Medicine, Director of Genitourinary Oncology Clinical Research, Dana-Farber Cancer Institute, Harvard Medical School, and co-principal investigator of ARMOR2, as an oral presentation during the Plenary Session 2 on Wednesday, November 19, 2014 at 2:05 p.m. (CET).
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
Business Wire - Tue Nov 04, 7:02AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Jodie Morrison, president and chief executive officer, will provide a company overview at two November investment conferences:
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Presents Updated Phase 2 Data on Galeterone in Patients with Advanced Prostate Cancer at ESMO 2014
Business Wire - Mon Sep 29, 7:01AM CDT
--Updated Data Supports Development in Patients with Splice Variants
TKAI: 11.52 (-0.35)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 32

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 89

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 73

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 40

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 18

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 192

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 62

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 74

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading

Top 5 Most Recently Viewed Articles

Legit Security Named as a Top Performer in Application Security

Updated Category News Views 210

Legit Security Recognized as a Leader in Application Security Legit Security, a leader in AI-native Application Security Posture Management (ASPM), has recently been acknowledged as a prominent player in the IDC MarketScape for ASPM. This achievement reflects the company's commitment to securing AI-powered application development processes. The IDC MarketScape report...

Continue Reading
Active Dental Transforms Patient Experience with New Website

Updated Category News Views 140

Active Dental Enhances Patient Accessibility with Unified Website Active Dental, a reputable family and general dentistry practice in the Dallas-Fort Worth metroplex, has launched a newly redesigned website that seamlessly integrates all five of its practice locations into a single, user-friendly digital platform. This significant upgrade aims to make appointment...

Continue Reading
Stork Club's Innovative Approach to Postpartum Depression Support

Updated Category News Views 229

Stork Club Innovates Reproductive Health Care Stork Club has recently launched an unprecedented initiative aimed at addressing postpartum depression (PPD) among working mothers. This pioneering program offers a seamless blend of digital diagnostics and therapy, leading to significant improvements in mental health outcomes. With up to 20% immediate relief from PPD symptoms...

Continue Reading
Investors Eye Class Action Against Fortrea Holdings, Inc.

Updated Category News Views 114

Understanding the Fortrea Holdings, Inc. Class Action Fortrea Holdings, Inc. (NASDAQ: FTRE) has gained attention due to rising investor concerns regarding its recent financial disclosures. Investors who have experienced losses over $100,000 are now presented with an opportunity to potentially lead a securities fraud lawsuit against the company. This lawsuit highlights...

Continue Reading
Alpha Tau Medical Plans Engagements at Key Healthcare Events

Updated Category News Views 91

Upcoming Participation in Major Healthcare Conferences Alpha Tau Medical Ltd., a leading developer of innovative cancer therapies, is gearing up for an exciting presence at significant healthcare conferences. The involvement of the Chief Financial Officer, Raphi Levy, at these events marks a pivotal opportunity for the company to showcase its groundbreaking...

Continue Reading